Immunoglobulin Market Forecasts to 2028 – Global Analysis By Product (Immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), Immunoglobulin E (IgE) and Immunoglobulin D (IgD)), Form (Liquid and Lyophilized), Mode Of Delivery (Intravenous

Immunoglobulin Market Forecasts to 2028 – Global Analysis By Product (Immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), Immunoglobulin E (IgE) and Immunoglobulin D (IgD)), Form (Liquid and Lyophilized), Mode Of Delivery (Intravenous and Subcutaneous), Application (Primary Immunodeficiency (PI), Secondary Immunodeficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Other Applications, End User (Hospitals, Clinics and Homecare) and By Geography

According tStratistics MRC, the Global Immunoglobulins Market is accounted for $15.13 billion in 2022 and is expected treach $27.55 billion by 2028 growing at a CAGR of 10.5% during the forecast period. Immunoglobulins refers ta class of polymers with heat distortion temperatures higher than 150 degrees Celsius. These materials have excellent properties like the ability twithstand extremely high temperatures, superior strength and rigidity, increased durability, and high chemical resistance. One of the main market drivers is the expanding use of 3D printing high-performance plastic in the manufacturing industry. A good strength-to-weight ratiin 3D printing plastic balances the heavy components in the products.

According tthe National Clinical Trial (NCT) Registry, as of March 9th, 2021, in the United States, there were around 50 immunoglobulin-based ongoing clinical trials across different phases of development, which shows a positive impact on the market.

Market Dynamics:

Driver:

Increasing prevalence of immunological disorders

The market share for immunoglobulins has grown as a result of an increase in immunological disorders that have caused people tseek out cutting-edge medical treatment. For off-label purposes, intravenous and subcutaneous immunoglobulin use has significantly increased. Global healthcare systems are extremely concerned about the growing senior population as well as the rising frequency of immunodeficiency and neurological illnesses. Thus, there is a rise in demand for novel intravenous immunoglobulin therapies due tincreased awareness and the need tensure effective treatment, which is anticipated tdrive market growth.

Restraint:

High cost associated with the therapy

The rising prevalence of immunological disorders and the availability of more drugs for their treatment are driving the market's expansion. However, the expensive nature of this therapy is severely restricting its uptake. The low insurance coverage and high price of plasma products in South Africa are limiting their uptake. Therefore, it is anticipated that higher costs brought on by insufficient reimbursement policies will limit the adoption of these products among the general public worldwide.

Opportunity:

Rapid urbanization

Fast food consumption is increasing among people as a result of rapid urbanization and busy schedules. One of the primary factors driving market growth is an increase in patients suffering from diseases such as multiple myeloma, Waldenstrom macroglobulinemia, and autoimmune disorders. Additionally, rising interest in personalized medicine and increased awareness of the importance of early diagnosis are other factors driving market expansion.

Threat:

Lack of skilled professionals

Immunoglobulin development is a time-consuming, expensive process that calls for substantial financial outlays, clinical trial experience, quality control measures, and technical capabilities. Due tthe strict regulations imposed by the regulators, immunoglobulin manufacturers are required tinvest in clinical trials and post-approval safety monitoring programs. Both qualified healthcare workers and those with the necessary training tadminister immunoglobulin therapies are in short supply. Additionally, there aren't many concerns in the medical community about the safety of this therapy. Therefore, a lack of knowledge and expertise may restrain market expansion.

Covid-19 Impact

The COVID-19 had a sizable effect on the market's expansion. Effective therapies for the treatment of patients with COVID-19 infection were urgently needed due tthe rise in cases and high mortality that resulted from it. Immunoglobulin therapy for COVID-19 infection may be useful in managing the condition. The market participants have concentrated on the product's development and research. For instance, in May 2020, the US Food and Drug Administration (FDA) approved Octapharma USA's application for an investigational new drug (IND) ttest the efficacy and safety of treating COVID-19 patients with severe disease progression with Octagam 10% therapy. The trial is scheduled ttake place in a phase three clinical trial. As a result, COVID-19 had a major influence on the market's expansion.

The liquid segment is expected tbe the largest during the forecast period

During the forecast period, the liquid segment is anticipated taccount for the largest share of the market for immunoglobulins. The widespread adoption of liquid immunoglobulin therapy across the globe is largely attributed tthe rising prevalence of autoimmune disorders and the growing range of liquid immunoglobulin therapy options. This, coupled with the cost-effectiveness of this drug form and nrequirement for further dilution, is another factor contributing tthe highest demand and adoption of liquid throughout the projection period, which is driving the segment expansion.

The intravenous segment is expected thave the highest CAGR during the forecast period

Due tthe rising preference for administering immunoglobulins through intravenous mode, this segment is anticipated tregister the highest CAGR during the projected timeframe. An injection or infusion method of drug administration intthe vein through a needle or tube is referred tas an intravenous mode of delivery. The main drivers of the segment's growth are the rising number of strategic initiatives involving intravenous immunoglobulin and the rising volume of R&D projects that have received regulatory authority approval. The segment is expanding as a result of more and more drug approvals.

Region with largest share:

The largest share of the immunoglobulin market was accounted for by North America during the forecast period. This is because immunoglobulin has received an increasing number of FDA approvals in the United States. Due tthe high prevalence of neurological, immunological, and other disorders, an increase in the local supply of intravenous immunoglobulin products, significant reimbursement coverage, and the presence of major market players. The region's medical innovations, rising consumer awareness of their own health, and new developments in antibody therapy are propelling market growth.

Region with highest CAGR:

Due trising healthcare reforms, government initiatives tmake expensive IG therapies more affordable, and rising healthcare costs, Asia Pacific is predicted tgrow at the highest CAGR during the forecast period. Countries like Japan, India, and other Southeast Asian nations currently consume significantly fewer immunoglobulins per person than the United States. However, the increasing number of patients suffering from immunodeficiencies and the availability of reimbursement for these drugs are poised tdrive consumption during the forecast period.

Key players in the market

Some of the key players profiled in the Immunoglobulins Market include ADMA Biologics, Inc., Baxter international Inc., BiProducts Laboratory Ltd., Biotest AG., China Biologic Products Holdings, Inc., Coram LLC, CSL Limited, Cygnus Technologies, Gentian Diagnostics AS, Green Cross Corp, Grifols, S.A., Haffkine Bio-Pharmaceutical Corporation Ltd, Hualan Biological Engineering Inc., J. Mitra & Co. Pvt. Ltd, Kamada Pharmaceuticals, Kedrion Biopharma Inc., LFB Group Mabtech, Momenta Pharmaceuticals, Octapharma AG, Option Care Enterprises, Inc., Shanghai RAAS and Takeda Pharmaceutical Company Limited.

Key Developments:

In August 2022, Argenx received marketing authorization for Argenx from the Europe Commission. It will be used tcure adult patients with widespread myasthenia gravis treated against acetylcholine receptors that are anti-acetylcholine receptor antibody positive.

In March 2022, Grifols received approval by several European Union member state health authorities as well as by the United Kingdom for XEMBIFY. It is an innovative 20% subcutaneous immunoglobulin (SCIG) that has been approved ttreat primary and selected secondary immunodeficiencies.

In January 2022, the European Union expanded the indication for cutaquig by Octapharma. It is a human immunoglobulin for subcutaneous administration. The expanded indication covers patients with any type of secondary immunodeficiency whneed immunoglobulin replacement therapy.

Products Covered:
• Immunoglobulin G (IgG)
• Immunoglobulin A (IgA)
• Immunoglobulin M (IgM)
• Immunoglobulin E (IgE)
• Immunoglobulin D (IgD)

Forms Covered:
• Liquid
• Lyophilized

Technologies Covered:
• Focused Deposition Modelling
• Selective Laser Sintering

Mode Of Deliveries Covered:
• Intravenous
• Subcutaneous

Applications Covered:
• Primary Immunodeficiency (PI)
• Secondary Immunodeficiency (SID)
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Guillain Barré Syndrome
• Immunodeficiency Diseases
• Chronic Lymphocytic Leukaemia
• Specific Antibody Deficiency
• Inflammatory Myopathies
• Immune Thrombocytopenic Purpura (ITP)
• Multifocal Motor Neuropathy (MMN)
• Other Applications

End Users Covered:
• Hospitals
• Clinics
• Homecare

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements